darifenacin vs trospium
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of darifenacin and trospium. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Enablex
Sanctura
Darifenacin (Enablex) is a medicine that helps control an overactive bladder. It reduces the feeling of needing to go to the bathroom so often.
Trospium chloride (Sanctura) helps control an overactive bladder. It reduces the feeling of needing to go to the bathroom often.
This medicine treats overactive bladder. If you have overactive bladder, you may feel a sudden need to urinate. You may also urinate more often than normal, or leak urine.
This medicine treats overactive bladder (OAB). OAB can cause a frequent and urgent need to urinate. It can also cause urge urinary incontinence, which is leaking urine when you feel a sudden need to go.
Darifenacin blocks certain receptors in the bladder. These receptors cause the bladder muscles to contract. By blocking them, the medicine helps the bladder relax and hold more urine.
Trospium chloride blocks the action of a chemical called acetylcholine. This chemical can cause bladder muscles to squeeze too much. By blocking acetylcholine, the medicine helps the bladder relax, reducing the urge to urinate.
- • Dry mouth
- • Constipation
- • Headache
- • Upset stomach
- • Nausea
- • Dry mouth
- • Constipation
- • Headache
- Peripheral Swelling 91
- Herpes Zoster 83
- Pneumonia Viral 79
- Anaemia 59
- Arthralgia 59
No adverse event reports.
If you have bladder problems that cause you to have trouble urinating, use darifenacin with caution because it could make it harder to urinate. Use caution if you have stomach or bowel blockage, as this medicine can make it worse. Darifenacin may cause sleepiness, so do not drive or operate heavy machinery until you know how it affects you. Angioedema (swelling of the face, lips, tongue, and/or throat) has been reported with darifenacin and can be life-threatening.
Trospium chloride should be used carefully if you have a bladder blockage or stomach problems, as it can cause you to not be able to urinate or have gastric retention. This medicine may cause swelling of the face, lips, tongue, or throat, which can be life-threatening. Get medical help right away if this happens. Trospium may cause sleepiness, so be careful driving or using machines until you know how it affects you.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if darifenacin will harm your unborn baby. Talk to your doctor if you are breastfeeding or plan to breastfeed, as it is not known if darifenacin passes into breast milk.
Tell your doctor if you are pregnant or plan to become pregnant. This medicine should only be used during pregnancy if clearly needed. It is not known if this medicine passes into breast milk, so talk to your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare darifenacin with
Compare trospium with
How to Read This darifenacin vs trospium Comparison
darifenacin is classified in the Anticholinergic (Overactive Bladder) drug class, while trospium sits within the Anticholinergic (Overactive Bladder) class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, darifenacin has 371 submissions while trospium has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for darifenacin or trospium.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.